Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

The article examines pharmaceutical market growth, company positioning, and the innovation potential in emerging markets. Read this and other preferred organization articles in this special issue.

Evaluating the Supply Chain in Emerging Markets

Pharmaceutical-industry executives from Merck & Co., Pfizer, and Covidien share their perspectives on their expectations and evaluation in the preferred-provider relationship. Read this and other preferred organization articles in this special issue.

Optimizing a Supply Network

Novartis Acquires Genoptix; Lilly Exec Becomes Savient CEO; and More.

Week of Jan. 24, 2011: Company and People Notes: Novartis Acquires Genoptix; Lilly Exec Becomes Savient CEO; and More.

Merck Teams with Parexel; Roche CFO to Retire; and More

Week of Jan. 17, 2011: Company and People Notes: Merck Teams with Parexel; Roche CFO to Retire; and More.

During the past few years, we've seen a growing interest in direct oral application products, evidenced by the large amount of products already available on the market.

Using Excipients In Powder Formulations

Orally disintegrating tablets (ODTs) are growing in popularity and their market value could exceed $13 billion in sales by 2015, based on current global growth trends.

The Growth Of ODTs

Iain Moore explains what progress has been made so far regarding EU plans to regulate excipients.

An Update On The EU's Plans For Excipient Regulation

Biologics are large molecular weight molecules primarily formulated for parenteral administration; however, there are some smaller biomolecules that have been formulated for oral use.

Using Excipients With Biologics

Excipients should be regulated to manage risk. Although, excipients are an integral part of a finished pharmaceutical product, the issue of regulation is complex.

Is There A Need For Stringent Regulations For Excipients?

Gilead Sciences to Acquire Arresto Biosciences; Sartorius Appoints Head of Lab Business; and More.

Ingredients